Stay updated on B-701 & Pembrolizumab in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the B-701 & Pembrolizumab in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the B-701 & Pembrolizumab in Urothelial Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:44:48.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the context of a Phase 1b/2 study involving a novel FGFR3 inhibitor (B-701) combined with pembrolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:35:20.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying health conditions and prior treatments required for inclusion in the study. Previously, this section had no information provided.
    Difference
    18%
    Check dated 2024-05-22T21:34:33.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:51:52.000Z thumbnail image

Stay in the know with updates to B-701 & Pembrolizumab in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the B-701 & Pembrolizumab in Urothelial Cancer Clinical Trial page.